EHA 2024 | Oral azacitidine maintenance in AML with MDS-related changes: insights from QUAZAR AML-001
Maria Teresa Voso, MD, University Tor Vergata, Rome, Italy, discusses a sub-analysis of the QUAZAR AML-001 (NCT01757535) study, which examined oral azacitidine maintenance therapy for patients with acute myeloid leukemia (AML) with myelodysplastic syndrome (MDS)-related changes. The study found that azacitidine significantly improved relapse-free survival (RFS) compared to placebo, suggesting it may effectively prolong survival and achieve measurable residual disease (MRD) negativity in this high-risk group. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
